Difference between revisions of "Human Avian Influenza"
| Line 15: | Line 15: | ||
The incubation period for influenza is relatively short, ranging from 7 to 67 hours with a median of 34 hours for influenza A and a median of 14 hours for influenza B.<ref> ''The communicable disease management and control handbook'', Hawker, Begg et al</ref> At this point most patients infected with both H5N1 and H7N9 have presented with signs and symptoms of severe respiratory infection, often with pneumonia which progresses to acute respiratory disease syndrome, impaired coagulation, multiorgan dysfunction (similar to that seen with seasonal influenza and H5N1 infection), fever and lymphopenia. However as H7N9 is the first of its type to infect humans the full spectrum of presentations is not well understood at this time. | The incubation period for influenza is relatively short, ranging from 7 to 67 hours with a median of 34 hours for influenza A and a median of 14 hours for influenza B.<ref> ''The communicable disease management and control handbook'', Hawker, Begg et al</ref> At this point most patients infected with both H5N1 and H7N9 have presented with signs and symptoms of severe respiratory infection, often with pneumonia which progresses to acute respiratory disease syndrome, impaired coagulation, multiorgan dysfunction (similar to that seen with seasonal influenza and H5N1 infection), fever and lymphopenia. However as H7N9 is the first of its type to infect humans the full spectrum of presentations is not well understood at this time. | ||
| + | |||
==Management== | ==Management== | ||
Clinical suspicion is essential in symptomatic travellers returning from areas where avian influenza transmission has been confirmed. Local policies will guide identification and management of cases. Current understanding of avian influenza suggests that the potential for human-to-human transmission is unknown and therefore infection control guidance advocates isolation and the use of appropriate PPE in cases under investigation for H7N9 infection.<ref>''Centers for Disease Control and Prevention: Interim Guidance for Infection Control Within Healthcare Settings When Caring for Patients with Confirmed, Probable, or Cases Under Investigation of Avian Influenza A(H7N9) Virus Infection.'' Available at: http://www.cdc.gov/flu/avianflu/h7n9-infection-control.htm Accessed on 23rd June 2013</ref><ref>Public Health England: Investigation & management of possible human cases of avian influenza A/H7N9, in travellers returning to the UK. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317138620910 Accessed on 23rd June 2013.</ref> | Clinical suspicion is essential in symptomatic travellers returning from areas where avian influenza transmission has been confirmed. Local policies will guide identification and management of cases. Current understanding of avian influenza suggests that the potential for human-to-human transmission is unknown and therefore infection control guidance advocates isolation and the use of appropriate PPE in cases under investigation for H7N9 infection.<ref>''Centers for Disease Control and Prevention: Interim Guidance for Infection Control Within Healthcare Settings When Caring for Patients with Confirmed, Probable, or Cases Under Investigation of Avian Influenza A(H7N9) Virus Infection.'' Available at: http://www.cdc.gov/flu/avianflu/h7n9-infection-control.htm Accessed on 23rd June 2013</ref><ref>Public Health England: Investigation & management of possible human cases of avian influenza A/H7N9, in travellers returning to the UK. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317138620910 Accessed on 23rd June 2013.</ref> | ||
| + | |||
==Diagnostics== | ==Diagnostics== | ||
| Line 25: | Line 27: | ||
<br><br> | <br><br> | ||
Rapid antigen detection methods have also been developed, mostly for diagnosing infection in humans though more recently some have been used in birds. Antigen detection methods have the advantage of being quick to use and are able to detect all influenza type A infections (due to the use of a monoclonal antibody against the nucleoprotein), however they have a low sensitivity and are expensive. | Rapid antigen detection methods have also been developed, mostly for diagnosing infection in humans though more recently some have been used in birds. Antigen detection methods have the advantage of being quick to use and are able to detect all influenza type A infections (due to the use of a monoclonal antibody against the nucleoprotein), however they have a low sensitivity and are expensive. | ||
| + | |||
==Treatment== | ==Treatment== | ||
| Line 41: | Line 44: | ||
<references /> | <references /> | ||
| − | + | {{OpenPages}} | |
| − | + | [[:Category:Orthomyxoviridae]] [[:Category:Avian_Viruses]] [[:Category:One Health]] | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Revision as of 09:11, 2 July 2013
Human Disease
Overview
The most recent cases reported in China on the 29th March 2013 involve the A/H7N9 subtype (hereafter referred to as H7N9), which has been shown to be more virulent in people than poultry. China confirmed three initial human cases, all of whom died. Currently (as of 29th April 2013) there are 126 confirmed cases of H7N9 in humans in China.[1]
The human and animal sequences have been shown to be closely related but diverse enough to conclude that the virus has been circulating for a while (probably amongst animals). The H7N9 strain identified in people has been found to have amino acid substitutions not found in poultry that are associated with further adaptation to humans.[2] This adaptation to mammals is of concern and suggests that further adaptation may occur.[3] Currently no animal outbreaks have been identified in the area surrounding the confirmed cases and only a small proportion of birds have tested positive for the virus. However 77% of those people infected with H7N9 have been exposed to poultry/swine (including live bird markets). Three family clusters of 2-3 cases each have been identified where limited human to human transmission may have occurred. [3] Of 71 cases reported with complete data, 54 had an underlying health condition and the median age was 61 years, compared to median age of 26 years for H5N1.[1]
At the moment it is thought that H7N9 was transmitted from healthy poultry or swine to people either directly or through contaminated environments.[4] As few H7N9 positive birds have been detected, this may indicate that the virus is widespread in poultry and is asymptomatic which could lead to silent spread of the virus.
The complete virus is a recombination of three viruses found in Asia, H7 of the virus has been found to be closest to that found in domestic ducks in Zhejiang and the N9 closest to the wild bird strain in South Korea. Genetic changes have also been found that lead to increased virus binding and replication in mammalian respiratory cells and thus increased severity of infection. Viral RNA shedding in people with the H7N9 has been prolonged (up to 11, 17 and 20 days).[2] The virus has been shown to be weakly pathogenic in poultry and testing of different populations for H7N9 specific antibodies may be helpful in finding the source, though viruses with H7 HA may not trigger a strong antibody response. No cases have been reported outside of China.
Infection
The incubation period for influenza is relatively short, ranging from 7 to 67 hours with a median of 34 hours for influenza A and a median of 14 hours for influenza B.[5] At this point most patients infected with both H5N1 and H7N9 have presented with signs and symptoms of severe respiratory infection, often with pneumonia which progresses to acute respiratory disease syndrome, impaired coagulation, multiorgan dysfunction (similar to that seen with seasonal influenza and H5N1 infection), fever and lymphopenia. However as H7N9 is the first of its type to infect humans the full spectrum of presentations is not well understood at this time.
Management
Clinical suspicion is essential in symptomatic travellers returning from areas where avian influenza transmission has been confirmed. Local policies will guide identification and management of cases. Current understanding of avian influenza suggests that the potential for human-to-human transmission is unknown and therefore infection control guidance advocates isolation and the use of appropriate PPE in cases under investigation for H7N9 infection.[6][7]
Diagnostics
The use of reverse transcriptase polymerase chain reaction (RT-PCR) and real time RT-PCR are becoming more frequent in the diagnosis of AI. Tracheal samples have been shown have higher specificity and sensitivity as compared with virus isolation, whereas faecal samples were less sensitive.[8] The ability to amplify the HA0 region may mean that it can be used for more specific diagnosis. Rapid one-step multiplex RT-PCR assays have been used to detect influenza viruses and the H5 avian virus in people have shown no cross reactivity with respiratory pathogens.[9]
Rapid antigen detection methods have also been developed, mostly for diagnosing infection in humans though more recently some have been used in birds. Antigen detection methods have the advantage of being quick to use and are able to detect all influenza type A infections (due to the use of a monoclonal antibody against the nucleoprotein), however they have a low sensitivity and are expensive.
Treatment
Humans cases of H7N9 infection are treated symptomatically.[1][2] The WHO recommends early treatment with a neuraminidase inhibitor in cases under investigation for H7N9 infection.[10] The Center for Disease Control echoes this point recommending that a neuraminidase inhibitor be administered at the earliest opportunity, even if more than 48 hours have passed since the onset of symptoms.[11] Public Health England (formerly the Health Protection Agency) produced an algorithm for the management of contacts of confirmed cases of H5N1 infection in 2009. This recommends that only close contacts of, and healthcare staff caring for a confirmed case require antiviral prophylaxis with Oseltamivir.[12]
Further Information
References
- ↑ 1.0 1.1 1.2 Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report, Emergence of Avian Influenza A(H7N9) Virus Causing Severe Human Illness — China, February–April 2013, May 10, 2013 / 62(18);366-371
- ↑ 2.0 2.1 2.2 Koopmans, M., de Jong, M.D. (2013), Avian influenza A H7N9 in Zhejiang, China, The Lancet, 26th April 2013
- ↑ 3.0 3.1 World Health Organisation Risk Assessment: Human infections with avian influenza A(H7N9) virus, 7 June 2013 . Available at: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/RiskAssessment_H7N9_07Jun13.pdf Accessed on 23rd June 2013.
- ↑ Qun Li, M.D., Lei Zhou, M.D., Minghao Zhou, Ph.D., Zhiping Chen, M.D., Furong Li, M.D., Huanyu Wu, M.D., Nijuan Xiang, M.D., Enfu Chen, M.P.H., Fenyang Tang, M.D., Dayan Wang, M.D., Ling Meng, M.D., Zhiheng Hong, M.D., Wenxiao Tu, M.D., Yang Cao, M.D., Leilei Li, Ph.D., Fan Ding, M.D., Bo Liu, M.D., Mei Wang, M.D., Rongheng Xie, M.D., Rongbao Gao, M.D., Xiaodan Li, M.D., Tian Bai, M.D., Shumei Zou, M.D., Jun He, M.D., Jiayu Hu, M.D., Yangting Xu, M.D., Chengliang Chai, M.D., Shiwen Wang, M.D., Yongjun Gao, M.D., Lianmei Jin, M.D., Yanping Zhang, M.D., Huiming Luo, M.D., Hongjie Yu, M.D., M.P.H., Lidong Gao, M.D., Xinghuo Pang, M.D., Guohua Liu, M.D., Yuelong Shu, Ph.D., Weizhong Yang, M.D., Timothy M. Uyeki, M.D., M.P.H., M.P.P., Yu Wang, M.D., Fan Wu, M.D., and Zijian Feng, M.D., M.P.H. (2013)Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) Outbreak in China, The New England Journal of Medicine, April 24th 2013
- ↑ The communicable disease management and control handbook, Hawker, Begg et al
- ↑ Centers for Disease Control and Prevention: Interim Guidance for Infection Control Within Healthcare Settings When Caring for Patients with Confirmed, Probable, or Cases Under Investigation of Avian Influenza A(H7N9) Virus Infection. Available at: http://www.cdc.gov/flu/avianflu/h7n9-infection-control.htm Accessed on 23rd June 2013
- ↑ Public Health England: Investigation & management of possible human cases of avian influenza A/H7N9, in travellers returning to the UK. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317138620910 Accessed on 23rd June 2013.
- ↑ Alexander, D.J.(2008) , Avian Influenza – Diagnosis, Zoonoses and Public Health Volume 55, Issue 1, pages 16–23, February 2008
- ↑ Choi, J-H., Kim M-S., Lee, J-Y., Lee N-J., Kwon, D., Kang, M.G., Kang, C.(2013), Development and evaluation of multiplex real-time RT-PCR assays for seasonal, pandemic A/H1pdm09 and avian A/H5 influenza viruses detection, Journal of Microbiology April 2013, Volume 51, Issue 2, pp 252-257
- ↑ World Health Organisation: Overview of the emergence and characteristics of the avian influenza A(H7N9) virus. Available at: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/WHO_H7N9_review_31May13.pdf Accessed on 23rd June 2013
- ↑ Centers for Disease Control and Prevention: Interim Guidance on the Use of Antiviral Agents for Treatment of Human Infections with Avian Influenza A (H7N9). Available at: http://www.cdc.gov/flu/avianflu/h7n9-antiviral-treatment.htm Accessed on 23rd June 2013
- ↑ Health Protection Agency: Management of asymptomatic contacts of confirmed human case(s) of avian influenza A/H5N1. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1230540128869 Accessed on 23rd June 2013.
Error in widget FBRecommend: unable to write file /var/www/wikivet.net/extensions/Widgets/compiled_templates/wrt6748c863557c24_96515363 Error in widget google+: unable to write file /var/www/wikivet.net/extensions/Widgets/compiled_templates/wrt6748c8635c66a7_51079478 Error in widget TwitterTweet: unable to write file /var/www/wikivet.net/extensions/Widgets/compiled_templates/wrt6748c863619640_13319592
|
| WikiVet® Introduction - Help WikiVet - Report a Problem |
Category:Orthomyxoviridae Category:Avian_Viruses Category:One Health